RxDoctor Payments Data

Steven Ramm, PA

Physician Assistant · New Windsor, NYNPI 1801876628

Payments from drug & device makers

$13,726in general payments, 2019–2025

Across 632 payments — averaging $21.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • Lilly USA, LLC$1K
  • GSK$1K
  • AbbVie$1K
  • Novo Nordisk$1K
  • Pfizer$1K
  • plus $5K from 38 others

What the payments were for

  • Food & beverage$13,65199%
  • Education$751%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,726 in reported general payments places this provider in the 95th percentile of 11,358 physician assistant providers in New York.

See all physician assistant providers in New York

Medicare billing

Part B allowed, 2024
$71,576
Medicare patients
260
Services billed
955

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol83$103,092
OzempicSemaglutide81$98,746
JardianceEmpagliflozin79$94,146
TrulicityDulaglutide45$66,692
MounjaroTirzepatide51$64,899
EliquisApixaban59$57,892
JanuviaSitagliptin Phosphate36$39,951
Trelegy ElliptaFluticasone/Umeclidin/Vilanter27$31,043
Breztri AerosphereBudesonide/Glycopyr/Formoterol23$19,288
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog12$18,942
Tresiba Flextouch U-200Insulin Degludec17$18,690
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr16$16,421
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog19$15,922
EntrestoSacubitril/Valsartan13$12,800
Breo ElliptaFluticasone/Vilanterol16$10,970

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$1,492$131,59296 claims
AstraZenecaFarxiga, Breztri Aerosphere$2,184$122,380106 claims
Novo NordiskOzempic$1,200$98,74681 claims
Boehringer IngelheimJardiance$858$94,14679 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$1,276$58,43459 claims
PfizerEliquis$1,088$57,89259 claims
NovartisEntresto$64$12,80013 claims
AbbVieSynthroid$1,202$1,09331 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 11,358 physician assistant providers in New York.

Other physician assistant in New Windsor

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →